Table 3 Frequent (> 5%) treatment-emergent adverse events (safety population)
AE category | Placebo (N = 25) | TLC599 12 mg (N = 26) | TLC599 18 mg (N = 24) |
|---|---|---|---|
Any adverse event | 17 (68%) | 18 (69%) | 20 (83%) |
Headache | 4 (16%) | 3 (12%) | 6 (25%) |
Nasopharyngitis | 3 (12%) | 4 (15%) | 1 (4%) |
Cortisol decreased | 0 | 2 (8%) | 6 (25%) |
Upper respiratory tract infection | 2 (8%) | 1 (4%) | 4 (17%) |
Arthralgia | 3 (12%) | 1 (4%) | 2 (8%) |
Glucocorticoid deficiency | 0 | 3 (12%) | 1 (4%) |
Bronchitis | 3 (12%) | 0 | 0 |
Cough | 0 | 0 | 2 (8%) |
Diarrhea | 0 | 3 (12%) | 0 |
Dyspepsia | 0 | 2 (8%) | 0 |
Lipase increased | 2 (8%) | 0 | 1 (4%) |
Toothache | 1 (4%) | 0 | 2 (8%) |
Urinary tract infection | 1 (4%) | 2 (8%) | 0 |
Chronic kidney disease | 2 (8%) | 0 | 0 |
Injury | 2 (8%) | 0 | 0 |